Human placenta - stem cell source for obtaining pancreatic progenitors

Vol. 56 No. 2 Suppl., 2015
This supplement was not sponsored by Outside Organizations.


Sergiu Susman, Dan Rus-Ciuca, Olga Soritau, Razvan Ciortea, Mihai Girlovanu, Dan Mihu, Carmen Mihaela Mihu

Objectives: The apparition of sugar diabetes is produced by the decrease of the number and capacity of beta cells to secrete insulin. Cell mass recovery through cell therapy might be one of the solutions for treating this disease. The use of various cell sources of different differentiation grades has been tried over the last years. Decoding the molecular mechanisms of the pancreatic morphogenesis is essential for obtaining cells having a phenotype, which would be very similar to the mature cells located in the pancreatic endocrine component. In this study, in order to obtain pancreatic progenitors, we used stem cells harvested from the mesenchymal component of the amniotic membrane, cells with particular immunological properties, which are effective in transplant. Materials and Methods: Isolated cells from the placenta (amniotic membrane) have undergone a three-stage differentiation protocol. The modulation of glucose concentration, the type of substrate (collagen + laminin) and the use of nicotinamide and exedin-4 were the main selective conditions of differentiation microenvironment. The differentiated cells were analyzed from the point of view of proteins (immunofluorescence - IF), gene expression (real-time polymerase chain reaction - RT-PCR) and morphological changes. Results: Isolated cells from the placenta membrane induced for pancreatic differentiation expressed transcription factors, which are characteristic for pancreatic progenitors (Pdx1 and PAX4). During the experiment, the cells modified their morphology by forming islet-like clusters. They were positively for dithizone staining and expressed insulin as shown by immunocytochemistry. Conclusions: The isolated cells from the placenta can be differentiated towards pancreatic progenitors by using specific protocols.

Corresponding author: Sergiu Susman, Lecturer, MD, PhD; e-mail:

Download PDF


Mircea-Sorin Ciolofan, Elena Ionita, Iulica Ionita, Carmen Aurelia Mogoanta, Florin Anghelina, Anca-Stefania Enescu, Diana Maria Ciobirca, Andrei Osman, Maria-Camelia Foarfa, Garofita Olivia Mateescu

Chondrosarcoma is a malignancy of the mesenchymal tissue derived from transformed cells that produce the cartilage matrix. In the neck area, it represents less than 0.5% of malignant tumor pathology. Chondrosarcoma of the hyoid bone is extremely rare, only 20 cases having been published so far (PubMed 2014). We present the case of a 30-year-old patient from the urban area, admitted in the ENT (Ear, Nose and Throat) Emergency Service with inspiratory dyspnea, dysphagia, stomatolalia, with evolutive and progressive clinical history of 2-3 months. Endoscopic examination revealed a pharyngolaryngeal tumor process located in the right vallecula, who by mass effect displaces the above-hyoid epiglottis. CT (computerized tomography) scan described a cervical polycystic tumor aspect, with multiple septae and inside calcifications with a diameter of 3-4 mm. Surgery consisted in removal of the tumor process together with the hyoid bone. Histopathological and especially immunohistochemical examination established the diagnosis of low-grade chondrosarcoma of the hyoid bone. For assessment of the phenotype of the tumor cells, the following immunohistochemical markers were used: p53, Ki67. The patient followed radiochemotherapic oncological treatment and returned for regular follow-ups. There was a positive development with no signs of regional or remote relapse or metastasis for 24 months after surgical treatment. Surgery is the treatment of choice, with complete removal of the tumor, with chemoradiation playing an adjuvant role. Regular tracking of the patient is mandatory.

Corresponding author: Mircea-Sorin Ciolofan, Assistant Professor, MD, PhD; e-mail:

Download PDF
Download cover
Download contents

Journal archive